摘要
目的:观察验证痛灵止胶囊对癌性疼痛缓解的临床有效性及安全性。方法:采用随机、平行对照实验方法,将癌性疼痛(气滞血瘀型)患者200例随机分为两组,每组100例。结果:中医证候疗效分析,实验组愈显率为76.00%,对照组愈显率为54.00%,两组比较有统计学意义(P<0.05)。实验组改善疼痛症状明显优于对照组(P<0.05),改善善太息、脉络瘀血、癥积等症状、体征两组无明显差异(P>0.05)。两组中医证候积分治疗后组内、组间比较均有统计学意义(P<0.05)。结论:痛灵止胶囊治疗癌性疼痛(气滞血瘀型)疗效确切,疗效优于天蟾胶囊,安全性较好,无明显不良反应。
Objective：To observe and verify clinical efficacy and safety of Tonglingzhi capsule on cancer pain relief.Methods：Randomized,parallel controlled trials were designed for comparative study of 200 patients with cancer pain syndrome（Qi stagnation blood stasis syndrome）,100 patients in each group.Results：The efficacy of traditional Chinese medicine symptom analysis,the experimental group markedly effective rate was 76.00%,the control group was 54.00%,the two groups was statistically significant（P0.05）.Experimental group mitigated the pain much better than the control group（P0.05）.To improved Shantaixi、vein congestion、disease product symptoms and signs showed no significant difference between the two groups（P0.05）.Two groups after treatment of TCM,comparisons in group and between groups were statistically significant（P0.05）.Conclusion：Tonglingzhi capsule has significant curative effect on treatment of cancer pain syndrome,efficacy is superior to Tianchan capsule,security and no obvious adverse reactions.
出处
《实用中西医结合临床》
2010年第4期11-12,共2页
Practical Clinical Journal of Integrated Traditional Chinese and Western Medicine
关键词
痛灵止胶囊
癌性疼痛
气滞血瘀型
中医药疗法
Tonglingzhi capsule
Cancer pain
Syndrome of Qi stagnation blood stasis
Chinese medicine treatment
